From 00180645de2cec9c65e215eed8fc0c9f4081eac4 Mon Sep 17 00:00:00 2001
From: Isabell Alexandra Guckes <isabell.guckes@uni-bielefeld.de>
Date: Wed, 25 Sep 2024 16:43:35 +0000
Subject: [PATCH] Update file drug-data.tsx
---
src/data/drug-data.tsx | 1 +
1 file changed, 1 insertion(+)
diff --git a/src/data/drug-data.tsx b/src/data/drug-data.tsx
index 4bff3253..3e15d263 100644
--- a/src/data/drug-data.tsx
+++ b/src/data/drug-data.tsx
@@ -31,6 +31,7 @@ export const drugdata: (Array<DrugDatensatz>) = [
{
//gibt 4 Modulator Beispiele
name: "Modulators",
+ picture: "...",
introduction: "CFTR modulators represent a significant advancement in CF treatment since they are small molecules improving the function of the defective CFTR protein in a mutation-specific way, which helps restore chloride ion transport across cell membranes. Notable pharmaceutical agents include Trikafta®, Symdeko®, Orkambi® and Kalydeco® [1]. These medications have been demonstrated to significantly improve lung function and reduce pulmonary exacerbations. However, they are expensive and may cause side effects such as liver enzyme elevations and cataracts in pediatric patients [2]. Furthermore, they are not suitable for all CF patients since only mutations which produce a CFTR channel can be supported by CFTR modulators, not those mutations which lead to a missing CFTR channel (knock out) [1], e.g. stop-mutations including p.Arg553Ter or p.Gly542Ter [3]. ",
examples: [
{
--
GitLab